321 related articles for article (PubMed ID: 30368624)
1. Contemporary treatment of metastatic renal cell carcinoma.
Wiechno P; Kucharz J; Sadowska M; Michalski W; Sikora-Kupis B; Jonska-Gmyrek J; Poniatowska G; Nietupski K; Ossolinski K; Demkow T
Med Oncol; 2018 Oct; 35(12):156. PubMed ID: 30368624
[TBL] [Abstract][Full Text] [Related]
2. What advances have been made in immune-therapy for renal cell carcinoma?
Verzoni E; Grassi P; Ratta R
Future Oncol; 2017 Apr; 13(8):665-668. PubMed ID: 28183189
[No Abstract] [Full Text] [Related]
3. [Immunotherapy of renal cell cancer].
Géczi L; Nagyiványi K; Maráz A
Magy Onkol; 2017 Jun; 61(2):126-131. PubMed ID: 28585613
[TBL] [Abstract][Full Text] [Related]
4. Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma.
Zarrabi K; Wu S
Curr Oncol Rep; 2018 Apr; 20(5):41. PubMed ID: 29611002
[TBL] [Abstract][Full Text] [Related]
5. New therapeutic developments in renal cell cancer.
Prenen H; Gil T; Awada A
Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
[TBL] [Abstract][Full Text] [Related]
6. Emerging therapeutic approaches in renal cell carcinoma.
Parekh H; Rini BI
Expert Rev Anticancer Ther; 2015; 15(11):1305-14. PubMed ID: 26376584
[TBL] [Abstract][Full Text] [Related]
7. T-cell checkpoint inhibitors in metastatic renal cell carcinoma.
Grünwald V
Curr Opin Urol; 2015 Sep; 25(5):411-5. PubMed ID: 26125506
[TBL] [Abstract][Full Text] [Related]
8. High-dose IL-2 for metastatic renal cell carcinoma: can the first antitumor immunotherapy be reinvented?
Muhitch JB; Schwaab T
Immunotherapy; 2014; 6(9):955-8. PubMed ID: 25341116
[No Abstract] [Full Text] [Related]
9. The Past, Present and Future of Immunotherapy for Metastatic Renal Cell Carcinoma.
Chang AJ; Zhao L; Zhu Z; Boulanger K; Xiao H; Wakefield MR; Bai Q; Fang Y
Anticancer Res; 2019 Jun; 39(6):2683-2687. PubMed ID: 31177102
[TBL] [Abstract][Full Text] [Related]
10. Interferon-α-based immunotherapy in metastatic renal cell carcinoma patients with the primary tumor in situ.
Shinohara N; Abe T; Sazawa A; Maruyama S; Shindo J; Sato S; Suzuki S; Nonomura K
Jpn J Clin Oncol; 2012 Feb; 42(2):113-9. PubMed ID: 22131341
[TBL] [Abstract][Full Text] [Related]
11. Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?
Di Nunno V; Gatto L; Fragomeno B; Cubelli M; Nobili E; Romano I; Santoni M; Pisconti S; Montironi R; Massari F
Future Oncol; 2018 Dec; 14(29):2997-2999. PubMed ID: 30411632
[No Abstract] [Full Text] [Related]
12. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
Ko JJ; Xie W; Kroeger N; Lee JL; Rini BI; Knox JJ; Bjarnason GA; Srinivas S; Pal SK; Yuasa T; Smoragiewicz M; Donskov F; Kanesvaran R; Wood L; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Choueiri TK; Heng DY
Lancet Oncol; 2015 Mar; 16(3):293-300. PubMed ID: 25681967
[TBL] [Abstract][Full Text] [Related]
13. New perspectives in the treatment of metastatic renal cell carcinoma.
Barrière J; Hoch B; Ferrero JM
Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e16-23. PubMed ID: 22099727
[TBL] [Abstract][Full Text] [Related]
14. Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies.
Thomas JS; Kabbinavar F
Crit Rev Oncol Hematol; 2015 Dec; 96(3):527-33. PubMed ID: 26299335
[TBL] [Abstract][Full Text] [Related]
15. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
[TBL] [Abstract][Full Text] [Related]
16. [Imaging of Metastastic Renal Cell Carcinoma under Therapy with Immune Checkpoint Inhibitors].
Notohamiprodjo M; Kopp HG; Bedke J
Rofo; 2017 Apr; 189(4):287-292. PubMed ID: 28335045
[No Abstract] [Full Text] [Related]
17. Duration of targeted therapy for metastatic renal cell carcinoma: a review of current practices.
Négrier S
Oncology; 2012; 82(4):189-96. PubMed ID: 22440948
[TBL] [Abstract][Full Text] [Related]
18. Prolonging survival in metastatic renal cell carcinoma patients treated with targeted anticancer agents: a single-center experience of treatment strategy modifications.
Ninomiya N; Tamada S; Kato M; Yamasaki T; Iguchi T; Nakatani T
Can J Urol; 2015 Jun; 22(3):7798-804. PubMed ID: 26068628
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
McDermott DF; Regan MM; Atkins MB
Clin Genitourin Cancer; 2006 Sep; 5(2):114-9. PubMed ID: 17026799
[TBL] [Abstract][Full Text] [Related]
20. Advances in immune-based therapies of renal cell carcinoma.
Lam JS; Belldegrun AS; Figlin RA
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]